Clinical Trials Logo

Sars-CoV2 clinical trials

View clinical trials related to Sars-CoV2.

Filter by:

NCT ID: NCT04393974 Recruiting - Cancer Clinical Trials

COVID-19 and Cancer Patients

OnCovid
Start date: March 24, 2020
Phase:
Study type: Observational

Routinely collected data will be used to assess the morbidity and mortality of cancer patients following a positive COVID-19 infection.

NCT ID: NCT04391829 Recruiting - COVID-19 Clinical Trials

Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males

COVIDSPERM
Start date: August 31, 2020
Phase: N/A
Study type: Interventional

The objectives of the study, are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

NCT ID: NCT04367350 Recruiting - COVID Clinical Trials

Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement

Start date: March 20, 2020
Phase:
Study type: Observational [Patient Registry]

Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.

NCT ID: NCT04367142 Recruiting - Sars-CoV2 Clinical Trials

Rapid Detection of COVID-19 by Portable and Connected Biosensor

COR-DIAL-1
Start date: August 24, 2020
Phase:
Study type: Observational

The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.

NCT ID: NCT04363450 Recruiting - COVID-19 Clinical Trials

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

HCQPreP
Start date: April 27, 2020
Phase: Phase 3
Study type: Interventional

This a double-blind, randomized, placebo-controlled clinical trial to determine if primary prophylaxis with hydroxychloroquine in healthcare workers reduces symptomatic COVID-19 infection. Healthcare workers will be randomized at a 1:1 allocation between intervention and placebo arms and followed for 12 weeks. This study will enroll up to 1,700 participates in Lafayette, Louisiana. The primary outcome will number of symptomatic COVID-19 infections. Secondary endpoints included number of days healthcare workers are absent from work and rate of severe infection.

NCT ID: NCT04362267 Recruiting - Sars-CoV2 Clinical Trials

Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital

PRECOVIA
Start date: June 15, 2020
Phase:
Study type: Observational

The aim of the study is to determine the incidence o of SARS-cov2 infection among health care workers highly exposed to covid 19 during 10 weeks et to analyze the determinants of their occupational and environmental exposure. Every 14 days, we performed SARS-Cov2 RT- PCR, serological testing and clinical questionnaire among a cohort of 100 HCW with a high degree of exposure to covid19 infection. Information about occupational exposure as the workplace, the activity of care, the characteristics of patient infected are captured, as well as environmental or personal exposure. The results will support the design of a new care organization and will define new ways of protection for patients (covid or not covid 19) and prevention for HCW.

NCT ID: NCT04354558 Recruiting - Sars-CoV2 Clinical Trials

French Single Centre Experience of Critically Ill Patients With Covid 19

CovidAmiens20
Start date: July 1, 2020
Phase:
Study type: Observational

Since the outbreak of a syndrome of acute respiratory distress associated to a novel coronavirus 2 (SARS-Cov2) that began in China, Europe and France have to face a sanitary emergency with critically care support when the patient evolves to an acute respiratory distress (ARDS). In the context of supply shortages (ventilators, bed capacities) that countries have to deal with, data were lacking of characteristics and outcomes of patients admitted to intensive care unit (ICU). the purpose of this project is to report the epidemiology and the outcomes of a French cohort of critically ill patients with SARS-Cov2

NCT ID: NCT04353609 Recruiting - Autoimmune Diseases Clinical Trials

Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases

covid19 fai2r
Start date: April 18, 2020
Phase:
Study type: Observational

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

NCT ID: NCT04349618 Recruiting - COVID19 Clinical Trials

Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia

VT4COVID
Start date: April 15, 2020
Phase: N/A
Study type: Interventional

Mortality of COVID-19 pneumonia with acute respiratory distress syndrome (ARDS) is extremely high in preliminary reports amounting to 50-60%. Duration of mechanical ventilation in these patients appears to exceed standard duration of mechanical ventilation in non-COVID-19 ARDS patients, suggesting that COVID-19 patients may be particularly at risk for ventilator-induced lung injury. Treatment of COVID-19 ARDS patients is to date mainly supportive with protective mechanical ventilation (ventilation with low tidal volume (VT) i.e. 6 ml/kg of predicted body weight (PBW) and plateau pressure control below 30 cm H2O). Mechanical ventilation with VT reduction below 6 ml/kg PBW in ARDS may reduce alveolar strain, driving pressure and hence ventilator-induced lung injury. Investigators recently performed a multicenter pilot study on 34 moderately severe to severe ARDS patients. This study demonstrated that ultraprotective ventilation with ultra-low VT (≤4.2 ml/kg PBW) without extracorporeal circulation may be applied in approximately 2/3 of the patients, with a 4 cmH2O median reduction in driving pressure, at the price of transient episodes of severe acidosis in approximately 1/3 of the patients. Investigators hypothesized that ultraprotective ventilation without extracorporeal circulation may reduce the mortality at day-90 and increase the number of days free from mechanical ventilation (VFD) at day-60, as compared to protective ventilation.

NCT ID: NCT04348864 Recruiting - COVID-19 Clinical Trials

COVID-19 Diagnostic Self-testing Using Virtual Point-of-care

Start date: April 16, 2020
Phase: N/A
Study type: Interventional

The goal of the research is to assess candidate COVID-19 rapid diagnostic tests (e.g. immunodiagnostic antibody tests, like Cellex qSARS-CoV-2 IgG/IgM Rapid Test, or antigen tests, like Turklab Test-It COVID-19 Home Test, AllBio Science Inc. and Artron Laboratories Inc. rapid COVID-19 antigen tests in order to judge their clinical accuracy compared to Centers for Disease Control (CDC)-recommended molecular genetic testing and clinical diagnosis. Second, it is our goal to determine if self-testing assisted by COVIDscanDX mobile device camera acquisition software platform and telemedicine clinical/technical support (virtual point-of-care) improves the ease of use and immediate interpretation of the tests, thus making self-testing comparable in accuracy and safety to testing in a clinical setting. Third, we are testing antibodies to SARS-CoV-2 after diagnosis with COVID-19 or following vaccination to measure the onset and time course of detectable antibodies from finger-stick blood drops and rapid antibody lateral flow tests. The overall purpose of the study is to dramatically increase the capacity of COVID-19 testing by establishing the safety, ease-of-use and validity of self-testing assisted by mobile device imaging and telemedicine remote support and provide evidence of antibody time-course response to vaccination.